ESR1 and breast cancer: In contrast to ER-positive/HER2-negtive breast cancer, ER+/HER2+ patients are less responsive to selective estrogen receptor modulators (SERMs), such as tamoxifen, and to aromatase inhibitors(AIs) [2], [3], [5].